Ethos Financial Group LLC Decreases Position in Pfizer Inc. (NYSE:PFE)

Ethos Financial Group LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 11.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,933 shares of the biopharmaceutical company’s stock after selling 1,956 shares during the quarter. Ethos Financial Group LLC’s holdings in Pfizer were worth $430,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of PFE. Briaud Financial Planning Inc acquired a new stake in shares of Pfizer in the 3rd quarter valued at $30,000. GoalVest Advisory LLC raised its holdings in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer in the 3rd quarter valued at $34,000. VisionPoint Advisory Group LLC raised its stake in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in Pfizer during the 4th quarter worth $36,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the topic of several research analyst reports. Morgan Stanley lifted their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. BMO Capital Markets restated an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $36.00.

Pfizer Price Performance

PFE stock traded down $0.07 during trading on Thursday, reaching $28.20. 47,806,405 shares of the company were exchanged, compared to its average volume of 43,591,230. The company has a market cap of $159.66 billion, a P/E ratio of -469.59, a PEG ratio of 1.17 and a beta of 0.63. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37. The stock’s 50 day moving average price is $26.94 and its 200 day moving average price is $28.12. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The firm’s revenue was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.23 earnings per share. As a group, analysts predict that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.96%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.